Interpersonal violence causes substantial morbidity and mortality worldwide and poses a considerable economic burden, equivalent to 4%-5% of the gross national product in certain countries (1). The Commonwealth of Puerto Rico is a U.S. territory with a 2004 population of approximately 3.9 million (2). In Puerto Rico, homicides were the 12th leading cause of death overall in 2003, ranking fifth among males and 15th among females (3). This report summarizes an analysis of death certificate data on violent deaths of children and young adults in Puerto Rico during 1999-2003, which determined that 93% of homicide victims aged <30 years were young males, the most common method of homicide was assault by firearm discharge, and the rate of homicide among males aged 25-29 years increased during the period. To address this problem, the Puerto Rican government has initiated a comprehensive strategy that includes enhancing an integrated surveillance system for fatal and nonfatal assault, supporting research on interpersonal violence, and establishing local prevention programs (e.g., violence prevention curricula in selected schools).
Homicides Among Children and Young Adults -Puerto Rico, 1999-2003
Interpersonal violence causes substantial morbidity and mortality worldwide and poses a considerable economic burden, equivalent to 4%-5% of the gross national product in certain countries (1) . The Commonwealth of Puerto Rico is a U.S. territory with a 2004 population of approximately 3.9 million (2) . In Puerto Rico, homicides were the 12th leading cause of death overall in 2003, ranking fifth among males and 15th among females (3) . This report summarizes an analysis of death certificate data on violent deaths of children and young adults in Puerto Rico during 1999-2003, which determined that 93% of homicide victims aged <30 years were young males, the most common method of homicide was assault by firearm discharge, and the rate of homicide among males aged 25-29 years increased during the period. To address this problem, the Puerto Rican government has initiated a comprehensive strategy that includes enhancing an integrated surveillance system for fatal and nonfatal assault, supporting research on interpersonal violence, and establishing local prevention programs (e.g., violence prevention curricula in selected schools).
The University of Puerto Rico Center for Hispanic Youth Violence Prevention obtained annual data from the Puerto Rico Health Department, Division of Statistics (3) on homicides among persons aged <30 years in Puerto Rico during 1999-2003 and examined the data by age group, sex, and method (e.g., assault by firearm discharge or assault by sharp object) for each year (4) . Homicide was defined as death resulting from an injury purposefully inflicted by another person (including legal intervention) for which the underlying cause listed on the death certificate corresponded to codes X85-Y09, Y35, and tims. Homicides occurred predominantly among males and in urban areas, and by firearms. The persistence of high homicide rates among young persons in Puerto Rico indicates a critical need for addressing potential contributors to interpersonal violence. The findings in this report are subject to at least three limitations. First, the data were obtained from death certificates, which lack information about the circumstances, perpetrator, and victim/perpetrator relationship. This limits the ability to describe certain types of homicides (e.g., child maltreatment versus peer assault) and their unique risk factors; age and sex distributions of homicides are likely to differ by type of homicide. Second, death certificates provide little or no information about socioeconomic status, an important risk factor for interpersonal violence (1) . Finally, death certificates might misclassify some homicides as other causes of death (7).
Recent studies indicate that approximately 90% of the estimated 520,000 homicides worldwide in 2000 occurred in lowto middle-income countries, including in Central and South America and the Caribbean (1) . In these regions, high levels of poverty and income inequality between communities are major contributors to social and family violence (7). A recent study of homicides in Puerto Rico during 1990-1999 concluded that the risk of dying from homicide in Puerto Rico was among the highest in the world (23.2 per 100,000, compared with a worldwide average of 10.7 per 100,000) (1, 8) ; homicide rates in Puerto Rico correlated directly with high population density (8).
Research on risk and protective factors has identified several potential contributors to youth interpersonal violence in Puerto Rico, including neighborhood environment, rapid urbanization, political violence, organized criminal activity, illegal drug use, and drug trafficking (7). Studies of violence in Central and South America also have demonstrated the influence of individual factors (e.g., age, sex, or exposure to aggression) and household factors (e.g., history of family violence or household beliefs that support violent solutions to conflict) on interpersonal violence (7). An understanding of these factors should aid in the development of violence prevention programs for Puerto Rican communities.
Multiple efforts have been initiated in Puerto Rico to address the problem of interpersonal violence. Since 2000, the Center for Hispanic Youth Violence Prevention has participated in the development, implementation, and evaluation of strategies to address violence among Hispanic youth from a public health perspective. Activities include conducting research on risk and protective factors, training health and education professionals in youth violence prevention competencies (e.g., recognizing at-risk youth), and adapting an evidence-based violence prevention curriculum for cultural appropriateness and evaluating its implementation with students in a high-risk community in San Juan (9).
The Puerto Rican government also has implemented several strategies to address the problem of violence, including distributing the World Report on Violence and Health (1) to community leaders and government health organizations, instituting increased police surveillance in high-crime neighborhoods, installing video equipment to monitor streets and alert law enforcement to criminal activity, and allocating resources to enhance forensic investigations. In addition, the governor-appointed Commission for Violence Prevention and the Puerto Rico Health Department are designing and implementing a pilot surveillance project that merges public health and criminal justice data on violent deaths, especially those among adolescents and young adults; the findings will be used to guide future public health initiatives to reduce and prevent violent deaths in Puerto Rico. These monitoring and data analysis activities will need to be integrated with comprehensive prevention strategies that include ongoing assessment of community needs, multisectoral collaboration, youth participation, and early intervention in the lives of at-risk youth to address risk and protective factors regarding interpersonal violence. (1) . GBS is a serious neurologic disorder involving inflammatory demyelination of the peripheral nerves. At the time of the first report, five confirmed cases of GBS after receipt of MCV4 had been reported to the Vaccine Adverse Events Reporting System (VAERS). During the 4 months since, three additional confirmed cases of GBS have been reported. This report describes two of these recent cases and provides additional data collected through February 2006. Because available evidence neither proves nor disproves a causal relation between MCV4 and GBS, further monitoring and studies are ongoing within VAERS and the Vaccine Safety Datalink (VSD). CDC continues to recommend use of MCV4 for persons for whom vaccination is indicated (1); the additional reported cases have not resulted in any change to that recommendation.
Case Reports
Brief clinical and epidemiologic descriptions of two of the newly reported cases follow. The third case is undergoing detailed clinical investigation but meets the provisional case definition for GBS. † Case 1. On August 8, 2005, a male aged 19 years from Arizona was vaccinated with MCV4. Approximately 25 days later, he experienced numbness and tingling in his hands and feet, followed by weakness in his legs, difficulty running, and decreased dexterity in his hands. In the month before neurologic symptom onset, he had no defined episode of respiratory or gastrointestinal illness. He had traveled to Mexico twice during the preceding 3 months. Electrophysiology studies revealed a diffuse neuropathic process with both demyelinating and axonal features, consistent with GBS. Testing for Epstein-Barr virus capsid IgG and IgM antibodies was negative. Testing for cytomegalovirus IgG and IgM antibodies also was negative, as were serologic studies for hepatitis A, B, and C to rule out other probable causes of GBS. The patient was treated with intravenous immunoglobulin. At follow-up examination 8 weeks after onset, he had fully recovered.
Case 2. On November 4, 2005, a male aged 17 years from Ohio received MCV4. Eleven days later, he experienced numbness and tingling in his right foot, followed by the same symptoms in the left foot, which progressed proximally during the next 5 days. He also described a neck hyperextension injury sustained while playing sports 2 days before the start of sensory symptoms and sore throat and congestion 1 day before sensory symptoms. He had no gastrointestinal illness during the 6 weeks before hospital admission, which occurred 6 days after symptom onset. Cervical spine radiographs revealed no fractures; magnetic resonance imaging (MRI) of the spine revealed mild enhancement along the surface of distal cord and lumbar nerve roots, consistent with GBS. Nerve conduction studies also were consistent with GBS. Polymerase chain reaction (PCR) assays for enterovirus were negative, as were tests for Mycoplasma pneumoniae IgG and IgM. The patient was treated with intravenous immunoglobulin. At follow-up examination 2 weeks after admission, he had completely recovered.
In the two cases described in this report, the period from MCV4 vaccination to symptom onset was less than 6 weeks. This is the time window of elevated risk noted for GBS after administration of certain other vaccines (2) .
To determine whether the reporting rate of GBS after MCV4 vaccination was higher than the expected incidence rate of GBS for the appropriate age group population, the reporting rate was calculated by dividing the eight confirmed GBS cases with onset within 6 weeks of vaccination by the number of vaccine doses distributed as provided by the manufacturer (approximately 3.77 million doses of MCV4 were distributed during March 2005-February 2006). The eight cases were divided by the 3.77 million distributed doses to provide the reporting rate for GBS after MCV4. The expected incidence rate of GBS was estimated from a multistate hospital discharge database (Health Care Utilization Project). § For the years 2000-2003, the incidence rate of GBS among persons aged 11-19 years was estimated to be 1.4 per 100,000 population per year or 0.17 per 100,000 population during a 6-week period. Therefore, the ratio of the reporting rate of GBS after MCV4 vaccination to the expected incidence rate was 1.4 (95% confidence interval = 0.7-2.8), suggesting that the occurrence of eight cases of GBS within 6 weeks of MCV4 administration is similar to what might be expected to occur by chance alone.
As part of the investigation, other possible causes of GBS, such as Campylobacter jejuni, were assessed. C. jejuni is a leading cause of gastroenteritis globally and the most frequent antecedent pathogen in GBS (3) . No evidence of C. jejuni was observed in any of the eight cases reported; however, many C. jejuni infections are asymptomatic. No serum samples from GBS cases reported after MCV4 vaccination were available for testing. To further assess the possibility that C. jejuni was a precipitating cause, unpublished data were collected and analyzed from all five state health departments involved in initial GBS case reports to VAERS (Arizona, New Jersey, New York, Ohio, and Pennsylvania). (1) . Since that time, three additional confirmed cases of GBS with onset within 6 weeks of MCV4 vaccination have been reported. However, even with these reported cases, the reported incidence remains similar to the expected incidence. In addition, three other cases of GBS have been reported, with symptom onsets at >6 weeks (107 days, 116 days, and 125 days) after vaccination with MCV4; these three cases were not included in calculation of GBS rates. Because VAERS is a voluntary reporting system, the completeness of reporting of GBS remains unknown. Only three cases were reported since October 2005, suggesting that MCV4 might not be causally related to GBS. The background incidence rate of GBS is one to two cases per 100,000 population. However, the timing of onset of neurologic symptoms within 2-5 weeks of vaccination is still a concern.
Additional preliminary data from VSD, ¶ a collaborative project between CDC and eight managed care organizations in the United States, have not identified GBS cases in MCV4 recipients. However, VSD has a limited ability to detect rare health events such as GBS. To further evaluate any potential risk, additional controlled studies of GBS after MCV4 are being planned.
The case definition developed for the initial investigation has been refined by an extended working group of the Brighton Collaboration,** an international voluntary collaboration of scientists. The Clinical Immunization Safety Assessment Network, † † in collaboration with CDC, continues to research and conduct standardized clinical evaluation of affected vaccinees to better understand the pathophysiology of select adverse events after vaccination, such as GBS. In response to the evaluation of the reported cases to VAERS, Sanofi Pasteur and FDA updated the Menactra vaccine package insert to list previous GBS as a contraindication and provide a warning of the temporal relation between GBS and MCV4 (4).
In October 2005, CDC recommended continuing use of MCV4 for persons for whom vaccination is recommended; the additional cases reported in this update do not affect that recommendation (1) . In December 2005, the Global Advisory Committee on Vaccine Safety also recommended no change in MCV4 vaccination policies (5) .
The Advisory Committee on Immunization Practices has recommended that persons with a history of GBS should not be vaccinated with MCV4 unless they are at elevated risk for meningococcal disease (6). Persons at elevated risk for meningococcal disease include first-year college students living in dormitories, military recruits, travelers to areas in which meningococcal disease is hyperendemic or epidemic, microbiologists who are routinely exposed to isolates of Neisseria meningitidis, patients with anatomic or functional asplenia, and patients with terminal complement deficiency. Information regarding the current investigation should be shared with adolescents and caregivers before MCV4 vaccination. A Vaccine Information Statement and fact sheet noting the information on the reported GBS cases is available at http://www. cdc.gov/nip/publications/vis/default.htm. An updated fact sheet for health-care workers is available at http://www. cdc.gov/nip/vacsafe/concerns/gbs/menactra.htm. CDC continues to recommend that health-care workers and any other persons aware of adverse events associated with MCV4 or any other vaccination report to VAERS cases of GBS or any other § Available at http://www.ahrq.gov/hcupnet. ¶ (Figure 1) , and an additional 14 persons with clinically compatible symptoms were being investigated in three neighboring states (11 in Illinois, two in Nebraska, and one in Minnesota) in what has become the largest epidemic of mumps in the United States since 1988 (1). This report summarizes and characterizes the ongoing mumps epidemic in Iowa, the public health response, and recommendations for preventing further transmission.
Mumps is an acute viral infection characterized by fever and nonsuppurative swelling of the salivary glands; an estimated 20%-30% of cases are asymptomatic. Complications can include inflammation of the testicles or ovaries, meningitis/ encephalitis, spontaneous abortion, and deafness. During the prevaccine era, nearly everyone in the United States experienced mumps, and 90% of cases occurred among children aged <15 years. In 1977, Iowa law mandated 1 dose of measles, mumps, and rubella (MMR) vaccine for entry to public schools; in 1991, the mandate became 2 doses. For the 2004-05 school year, 97% of children entering school in Iowa had received 2 doses of MMR vaccine (2) .
The first reports to the Iowa Department of Public Health (IDPH) of mumps-like illness occurred in December 2005 at a university in eastern Iowa, where several students with glandular swelling were tested; two tested positive for mumpsspecific IgM antibodies. In mid-January 2006, an isolate from an unrelated patient was cultured and identified as mumps virus at the University Hygienic Laboratory (Iowa's state public health laboratory). Viral isolates were sent to CDC, and the mumps strain was identified as genotype G. By midFebruary, active surveillance had been initiated in seven geographic areas, including the campuses of the three largest universities in Iowa. Of the 219 cases reported in Iowa, the median patient age was 21 years (range: 3-85 years), with 48% of patients aged 17-25 years ( Figure 2 ); 30% (34 of 114) were known to be college students. Of the 133 patients with investigated vaccine history, 87 (65%) had documentation of receiving 2 doses, 19 (14%) 1 dose, and eight (6%) no doses; vaccine status could not be documented in 19 (14%) patients. Among the 114 patients for whom symptomatic information was available, the most common symptoms were parotitis in 94 (83%) patients, submaxillary/sublingual gland swelling in 46 (40%), fever in 41 (36%), and sore throat in 36 (32%); average duration of illness was 5.1 days. Six (5%) patients reported complications (e.g., orchitis); one suspected case of encephalitis is being investigated. As of March 28, 2006, investigators had determined that only 36 (16%) of the 219 cases were linked epidemiologically (i.e., a source of infection was identified), suggesting frequent unapparent transmission.
The source of the Iowa epidemic is unknown; however, the United Kingdom (UK) experienced a recent mumps epidemic that peaked during 2005 with approximately 56,000 cases and a high attack rate among young adults (3). The mumps strain in the UK epidemic also was identified as genotype G (4), and the UK epidemic has been linked to a 2005 mumps outbreak in the United States (5).
To educate health-care professionals in Iowa regarding the epidemic and mumps, information has been distributed via Iowa's Health Alert Network (HAN), in weekly electronic newsletters, and via frequent conference calls. The IDPH website ¶ has provided biweekly updates, county case counts, fact sheets, and guidance to local health departments and health-care facilities on case investigations. IDPH recommendations include 1) requesting at least 5 days of isolation for all patients (quarantine is not being used), 2) ensuring that students and staff members on all Iowa college campuses have had 2 doses of MMR or are immune from mumps (6), 3) assessing vaccination status of all health-care professionals in Iowa and offering vaccination where appropriate (7), and 4) sending all specimens collected from possible cases to University Hygienic Laboratory for testing.
Despite control efforts and a highly vaccinated population, this epidemic has spread across Iowa and potentially to neighboring states. Ongoing investigations will focus on identifying actual vaccine coverage on college campuses, potential modes of mumps transmission, and the effectiveness of 1 or 2 doses of MMR. During March 19-25, 2006,* the number of states reporting widespread influenza activity † decreased to 16. Sixteen states reported regional activity, 13 reported local activity, and five reported sporadic activity (Figure 1 ). § The percentage of specimens testing positive for influenza remained at the same level as recent weeks in the United States. During the preceding 3 weeks (weeks 10-12), the percentage of specimens testing positive for influenza ranged from 30.6% and 28.6% in the South Atlantic and East South Central regions, respectively, to 9.7% in the Pacific region. 
Laboratory Surveillance
During March 19-25, World Health Organization (WHO) collaborating laboratories and National Respiratory and Enteric Virus Surveillance System (NREVSS) laboratories in the United States reported testing 3,158 specimens for influenza viruses, of which 681 (21.6%) were positive. Of these, 77 were influenza A (H3N2) viruses, 70 were influenza A (H1N1) viruses, 347 were influenza A viruses that were not subtyped, and 187 were influenza B viruses.
Since October 2, 2005, WHO and NREVSS laboratories have tested 110,066 specimens for influenza viruses, of which 13,532 (12.3%) were positive. Of these, 11,989 (88.6%) were influenza A viruses, and 1,543 (11.4%) were influenza B viruses. Of the 11,989 influenza A viruses, 4,875 (40.7%) have been subtyped; 4,629 (95.0%) were influenza A (H3N2) viruses, and 246 (5.0%) were influenza A (H1N1) viruses.
* Provisional data reported as of March 24. Additional information about influenza activity is updated each Friday and is available from CDC at http://www.cdc.gov/flu. † Levels of activity are 1) widespread: outbreaks of influenza or increases in influenza-like illness (ILI) cases and recent laboratory-confirmed influenza in at least half the regions of a state; 2) regional: outbreaks of influenza or increases in ILI cases and recent laboratory-confirmed influenza in at least two but less than half the regions of a state; 3) local: outbreaks of influenza or increases in ILI cases and recent laboratory-confirmed influenza in a single region of a state; 4) sporadic: small numbers of laboratory-confirmed influenza cases or a single influenza outbreak reported but no increase in cases of ILI; and 5) no activity. 
P&I Mortality and ILI Surveillance
During the week ending March 25, P&I accounted for 7.7% of all deaths reported through the 122 Cities Mortality Reporting System. This percentage is below the epidemic threshold † † of 8.2% (Figure 2 ).
The percentage of patient visits for ILI was 2.5%, which is above the national baseline of 2.2% (Figure 3 ). The percentage of patient visits for ILI ranged from 1.4% in the East South Central region to 3.5% in the West South Central region. 
Pediatric Deaths and Hospitalizations
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Notice to Readers
Discontinuation of Spectinomycin
In Historically, spectinomycin has been used to treat persons infected with Neisseria gonorrhoeae who cannot receive one of the two first-line treatments (i.e., fluoroquinolones or thirdgeneration cephalosporins) currently recommended for treatment of uncomplicated gonococcal infection (1). Relatively few indications exist for which spectinomycin is the preferred treatment option for N. gonorrhoeae; these include 1) pregnant women with penicillin or cephalosporin allergy (fluoroquinolones are contraindicated during pregnancy), 2) persons with penicillin or cephalosporin allergies who reside in areas with a high prevalence of quinolone-resistant N. gonorrhoeae (1,2), and 3) men with penicillin or cephalosporin allergies who have sex with men (3). No acceptable alternatives to spectinomycin therapy are currently available. Persons with penicillin or cephalosporin allergies who cannot receive fluoroquinolones can be desensitized to cephalosporins before treatment (4). Although 2 grams of azithromycin orally in a single dose is effective against uncomplicated gonococcal infection, no data are available to assess the safety and efficacy of this regimen in pregnant women. Moreover, concerns exist regarding the emergence of antimicrobial resistance if azithromycin is used widely in the treatment of N. gonorrhoeae.
Notice to Readers
National Child Abuse Prevention Month -April 2006
April is National Child Abuse Prevention Month (NCAPM). This year's theme is Safe Children and Healthy Families are a Shared Responsibility. Communities throughout the United States will be holding blue ribbon campaigns to promote healthy families, organizing educational fairs, and honoring parenting heroes.
Many cases of child maltreatment go unreported to authorities. However, approximately 906,000 children in the United States were confirmed by child protective services as being abused or neglected in 2003, a rate of 12.4 per 1,000 children (1). Of the reported cases, 5% involved emotional or psychological abuse, 10% involved sexual abuse, 9% involved physical abuse, and 61% involved neglect (1) . Persistent stress resulting from child maltreatment can disrupt early brain development and impair development of the nervous and immune response systems (2) . Children who experience maltreatment are at increased risk for adverse health effects throughout their lives (e.g., suicide, obesity, smoking, alcoholism, drug abuse, depression, eating disorders, sexual promiscuity, and certain chronic diseases) (3, 4) . In addition, persons who are abused as children are twice as likely to be assaulted as adults (5) .
NCAPM is an opportunity to raise awareness about child maltreatment and its devastating effects. Information about child maltreatment is available online from CDC at 
Notice to Readers
Sexual Assault Awareness MonthApril 2006
April is Sexual Assault Awareness Month (SAAM). Throughout the month, CDC encourages communities to promote healthy relationships and to increase awareness about the devastating impact of sexual violence.
Sexual violence affects persons at all stages of life. In 2003, approximately two out of 1,000 children in the United States were confirmed by child protective services as having been sexually assaulted (1) . Many sexually abused children, however, are not identified by child protective services. In 2003, approximately 9% of high school students reported having been forced to have sexual intercourse (2) . At least one in six women and one in 33 men in the United States have been victims of rape or attempted rape in their lifetime (3) .
The consequences of sexual violence can be severe. Survivors can suffer short-term physical injuries, including genital tearing, bruises, and broken bones (4). Long-term health consequences can include sexually transmitted diseases, irritable bowel syndrome, gastrointestinal problems, and chronic neck, back, and facial pain (5). In addition, survivors often face serious mental health problems, including post-traumatic stress disorder (4). Many survivors do not tell friends and family about the assault and consequently suffer the physical and psychological consequences alone (4) . Those who do disclose their abuse might be stigmatized by their family, friends, and communities.
Communities are encouraged to plan activities in recognition of SAAM. A calendar of national, state, and local events is available at http://www.nsvrc.org. Information about sexual violence is available at http://www.cdc.gov/injury. SAAM materials are available from the National Sexual Violence Resource Center, 123 North Enola Drive, Enola, PA 17025; telephone 877-739-3895 and at http://www.nsvrc.org.
Notice to Readers
Autism Awareness Month -April 2006
Autism spectrum disorders (ASDs) are lifelong developmental disabilities characterized by unusual social and communication development and the presence of unusual or repetitive behaviors and interests (1). These conditions affect an estimated 2-6 per 1,000 children (2), making autism a serious public health concern. Early identification and intervention can help children progress in their development and show improvements in their language, cognitive, social, motor, and other developmental skills (3).
April is Autism Awareness Month. In collaboration with partners, CDC is conducting a public awareness campaign to educate health-care and child-care providers regarding potential early warning signs of autism and other developmental disabilities. Additional information about autism and the CDC campaign are available at http://www.cdc.gov/autism and http://www.cdc.gov/actearly. Ambulance diversion occurs when EDs are too crowded to handle any more critically ill or injured patients and request that ambulances bypass them for another hospital. In 2003, an estimated 45% of hospital EDs were on diversion status at some time during the previous year. Ambulance diversions were more common in EDs with larger volumes of patients and those in metropolitan areas. 
Notice to Readers
Introduction of New Table IV Postponed
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